Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923514 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRPOLBKDM4ELMNA | |
| SCHEMBL7132970 | 0.83 | SMN1; SMN2 (0.51) | ALDH1A1TSHRPOLBHSD17B10KDM4E | |
| SCHEMBL6829232 | 0.83 | NPC1 (0.50) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6926049 | 0.83 | HSD17B10 (0.57) | ALDH1A1TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6919445 | 0.80 | MAOB (0.44) | ALDH1A1TSHRNPC1RAB9AKMT2A | |
| SCHEMBL7133523 | 0.80 | NPC1 (0.60) | ALDH1A1TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6831252 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22289462 | 0.78 | TSHR (0.50) | ALDH1A1TSHRPOLBKDM4ELMNA | |
| SCHEMBL278333 | 0.77 | ALDH1A1 (0.61) | ALDH1A1TSHRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6441520 | 0.76 | DAO (0.49) | ALDH1A1TSHRPOLBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-03 | — | — | US | disclosed |
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2022-05-03 | — | — | US | disclosed |
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-19 | — | — | US | disclosed |
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-19 | — | — | US | disclosed |
| US-10875834-B2 | Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-17 | — | — | US | disclosed |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-17 | — | — | US | disclosed |
| US-20190256483-A1 | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-22 | — | — | US | disclosed |
| EP-3490980-A1 | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES | Virginia Commonwealth University (US) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018018035-A1 | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018018035-A1 | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2004037808-A1 | 2 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AND ANTITUMOR COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149012-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885TSHR 3524/4885CYP1A2 765/4885 |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885TSHR 211/4885CYP1A2 2662/4885 |
| US-10836729-B1 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885TSHR 3524/4885CYP1A2 765/4885 |
| US-10875834-B2 | Prodrug and protected forms of 5-hydroxymethylfurfuranal (5-HMF) and its derivatives | MTHFD1, MTHFD2, ADH5 | ALDH1A1 27/4885TSHR 2756/4885CYP1A2 105/4885 |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885TSHR 211/4885CYP1A2 2662/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885TSHR 211/4885CYP1A2 2662/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885TSHR 211/4885CYP1A2 2662/4885 |
| US-11319292-B2 | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | HIF1AN, HMOX2, HIF1A | ALDH1A1 307/4885TSHR 3524/4885CYP1A2 765/4885 |
| US-20190256483-A1 | PRODRUG AND PROTECTED FORMS OF 5-HYDROXYMETHYLFURFURANAL (5-HMF) AND ITS DERIVATIVES | MTHFD1, MTHFD2, ADH5 | ALDH1A1 27/4885TSHR 2756/4885CYP1A2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.